Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-TKI”

17 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 17 of 17 results

Testing effectiveness (Phase 2)Looking for participantsNCT05456256
What this trial is testing

LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Who this might be right for
Adenocarcinoma of LungCarcinoma, Non-Small-Cell Lung
Lantern Pharma Inc. 90
Testing effectiveness (Phase 2)UnknownNCT05869162
What this trial is testing

Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI

Who this might be right for
Non-small-cell Lung Carcinoma
Shouyao Holdings (Beijing) Co. LTD 153
Not applicableStudy completedNCT04647110
What this trial is testing

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Who this might be right for
ALK-positive NSCLC
Pfizer 549
Testing effectiveness (Phase 2)Looking for participantsNCT05014464
What this trial is testing

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 90
Not applicableStudy completedNCT06282991
What this trial is testing

Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Who this might be right for
Non-Small Cell Lung Carcinoma
Pfizer 73
Not applicableActive Not RecruitingNCT05370469
What this trial is testing

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

Who this might be right for
Lung CancerEGFR Gene MutationEGFR+6 more
University of Virginia 30
Testing effectiveness (Phase 2)UnknownNCT05178511
What this trial is testing

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

Who this might be right for
The Diagnosis Was ALK Positive NSCLCSecond Generation ALK-TKI is ResistantEfficacy of Ensatinib in This Subset of Patients
Li Zhang, MD 40
Testing effectiveness (Phase 2)UnknownNCT05380024
What this trial is testing

Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Peking University Cancer Hospital & Institute 10
Not applicableLooking for participantsNCT03042221
What this trial is testing

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Who this might be right for
Non-Small Cell Carcinoma of Lung, TNM Stage 4Non-Small Cell Lung CancerEGFR Gene Mutation+3 more
University of Colorado, Denver 100
Testing effectiveness (Phase 2)Looking for participantsNCT03093116
What this trial is testing

Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who this might be right for
Locally Advanced Solid TumorsMetastatic Solid Tumors
Turning Point Therapeutics, Inc. 500
Early research (Phase 1)Ended earlyNCT04849273
What this trial is testing

TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

Who this might be right for
Non Small Cell Lung CancerNon-Small Cell Lung CancerNSCLC+3 more
Turning Point Therapeutics, Inc. 11
Testing effectiveness (Phase 2)Active Not RecruitingNCT05845671
What this trial is testing

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

Who this might be right for
Lung CancerNon Small Cell Lung Cancer
University of Colorado, Denver 12
Large-scale testing (Phase 3)Looking for participantsNCT06643416
What this trial is testing

Efficacy and Safety of Add-on Timolol for EGFR-TKI and ALK-TKI Induced Paronychia

Who this might be right for
ParonychiaEGFR-TKIALK-TKI
Queen Mary Hospital, Hong Kong 40
Testing effectiveness (Phase 2)Looking for participantsNCT05284539
What this trial is testing

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
Hunan Province Tumor Hospital 760
Post-approval studies (Phase 4)Study completedNCT04362072
What this trial is testing

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
CarcinomaNon-Small-Cell Lung
Pfizer 71
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944772
What this trial is testing

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Who this might be right for
Non-Small Cell Lung Cancer
AstraZeneca 247
Large-scale testing (Phase 3)Looking for participantsNCT06765109
What this trial is testing

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

Who this might be right for
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positive
Nuvalent Inc. 450